There’s always at least one reason behind why a family decides to move somewhere different. Perhaps it’s because of a new job ...

Verdiva Bio Limited ("Verdiva" or "the Company") today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other ...

Amy also shares the importance of getting to know the individuals behind the big Pharma logos, which helps patients ... dialogue that never existed before. Roche Diabetes Care in the US approached ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

CNBC's Angelica Peebles talks to Roche Pharma CEO Teresa Graham discusses why we're still in the early stages of the obesity ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...

Roche Holding AG's acquisition of Poseida for $1.5bn is a smart move by Big Pharma as allogeneic cell therapies are becoming increasingly de-risked. Despite recent challenges, Roche's diverse ...

ZURICH, Jan 8 (Reuters) - Roche (ROG.S), opens new tab on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics (PSTX.O), opens new tab ...

In a report released today, James Quigley from Goldman Sachs maintained a Sell rating on Roche Holding AG (RHHVF – Research Report), with a ...